This study investigates the safety of radioembolization therapy using Yttrium 90 for treating liver disease. Radioembolization is a procedure that delivers radiation directly to the liver to target cancer cells, specifically for hepatocellular carcinoma (HCC).
Participants will undergo various procedures related to the therapy, including pre-treatment, during treatment, and post-treatment evaluations. These procedures are necessary to monitor the effects and safety of the treatment.
- Who can participate: Adults diagnosed with hepatocellular carcinoma (HCC) who are planning to undergo Y-90 radioembolization therapy at Indiana University Health Hospital are eligible. Participants must be able to comply with all required procedures and visits.
- Study details: Participants will receive radioembolization therapy with Yttrium 90, which involves delivering radiation directly to the liver.
How understandable was the trial content above?
Hard to understand
Easy to understand
